Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02620384 · ClinicalTrials.gov registry record · Phase 3
Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure (MELT-HF)--A Single Center Pilot Study.
A Phase 3 study, sponsored by Aultman Health Foundation.
- Terminated
- Registry status
- Phase 3
- Development phase
- 147
- Enrollment target
NCT02620384 is a Phase 3 study that was terminated before completion, run by Aultman Health Foundation. The registered enrollment target is 147 participants.
The verdict
NCT02620384, a Phase 3 study, was terminated before completion, sponsored by Aultman Health Foundation.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 147 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine efficacy of metolazone as synergistic therapy with Lasix in patients with acute decompensated heart failure. This will be a single center double blinded randomized placebo- controlled pilot study of the addition of 5 mg of metolazone per day for 2 days compared to placebo in patients admitted with acute decompensated heart failure.
Interventions
- DRUG Experimental: Placebo
- DRUG Experimental: Metolazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2015-10-01 |
| Est. Completion | 2017-12-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02620384
The ClinicalTrials.gov registry entry for NCT02620384 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 147 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aultman Health Foundation, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Experimental: Placebo is the first listed.
NCT02620384 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02620384 about?
NCT02620384 is a clinical study titled "Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure (MELT-HF)--A Single Center Pilot Study.". The primary objective of the study is to determine efficacy of metolazone as synergistic therapy with Lasix in patients with acute decompensated heart failure. This will be a single center double blinded randomized placebo- controlled pilot study of the addition of 5 mg of metolazone per day for 2 d...
What is the current status of trial NCT02620384?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 147 participants. The study started on 2015-10-01. Estimated completion is 2017-12-29.
What interventions are being tested in trial NCT02620384?
The interventions under investigation include: Experimental: Placebo (DRUG), Experimental: Metolazone (DRUG).
Who is sponsoring clinical trial NCT02620384?
This trial is sponsored by Aultman Health Foundation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.